Surprisingly rapid regrowth of unused brain connections after decades of near blindness
Since 2007, clinical trials using gene therapy have resulted in often-dramatic sight restoration for dozens of children and adults who were otherwise doomed to blindness. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children’s Hospital of Philadelphia (CHOP), have found evidence that this sight restoration leads to strengthening of visual pathways in the brain, published this week in Science Translational Medicine.
“The patients had received the gene therapy in just one eye (their worse seeing eye), and though we imaged their brains only about two years later, on average, we saw big differences between the side of the brain connected to the treated region of the injected eye and the side connected to the untreated eye,” said lead author Manzar Ashtari, PhD, director of CNS Imaging at the Center for Advanced Retinal and Ocular Therapeutics in the Department of Ophthalmology at Penn. Ashtari is the former director of Diffusion Tensor Image Analyses and Brain Morphometry at CHOP.
“It’s an elegant demonstration that these visual processing pathways can be restored even long after the period when it was thought there would be a loss of plasticity,” said senior author Jean Bennett, MD, PhD, the F.M. Kirby Professor of Ophthalmology at Penn and director of the Center for Advanced Retinal and Ocular Therapeutics.
The team examined ten patients who have Leber’s congenital amaurosis Type 2 (LCA2), a rare disease that afflicts those who inherit a bad copy of an LCA2 gene from each parent, LCA2 causes their retinas to degenerate slowly and they typically have limited visual function at birth and then experience progressive loss of their remaining vision, rendering them completely blind by mid-life.
In one of the first great success stories for gene therapy, Bennett’s team and others demonstrated the effectiveness of LCA2 gene augmentation in animal tests stretching back to the early 2000s. The basic strategy is to inject a harmless virus that inserts good copies of the normal LCA2 gene into retinal cells. Patients who have received the gene therapy have commonly gone from being blind or near blind to being partially sighted and able to navigate almost normally.
One question hanging over the field has been: even if retinal function improves, how well can the brain’s visual processing pathways recover, after years of near-total blindness in which those unused pathways inevitably will have weakened?
Ashtari, a neuroimaging specialist, addressed this question with several experiments. First she compared the LCA2 group, which had initially received the gene therapy in one eye for safety reasons, to an age-matched control group with normal vision.
Using an advanced method of MRI technique to uncover deep brain connections, she found that while the connectivity of the visual pathway from the treated eye in LCA2 patients was similar to that of sighted controls, the untreated eye showed weaker connectivity to the brain as compared to the connections for the treated side. The data showed that the retina-brain pathways in the treated eyes in the LCA2 group seemed nearly as robust as the corresponding pathways in the sighted control group, implying that these pathways had largely rebuilt themselves in the LCA2 patients, following their retinal intervention.
“That was what we expected to see— the more the treated eye sees the world and interacts with the environment the more it stimulates the pathway and the stronger the connecting pathway becomes between the retina and the brain,” said Ashtari.
The result came despite the fact that many of the LCA2 patients were in their 20s, and one was even 45—an age when the ability of the nervous system to rewire itself is thought to be greatly reduced.
Ashtari also found a strong hint in the data that the treated-eye pathways tended to be in better shape when more time had elapsed since the treatment, implying that these pathways continue to improve with use. By contrast, the untreated-eye pathways showed a clear decline with time.
The Latest on: Vision-Restoring Gene Therapy
[google_news title=”” keyword=”Vision-Restoring Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vision-Restoring Gene Therapy
- Nanoscope Therapeutics Names New Vice President of Qualityon January 11, 2023 at 2:49 pm
Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies for retinal degenerative ... continued advancement of our optogenetic therapies to restore ...
- Seeking Enlightenment: The Quest To Restore Vision In Humanson January 5, 2023 at 4:00 pm
More recently, the possibility of restoring ... injury-induced vision loss through epigenetic reprogramming (bioRxiv preprint version). Obviously, the goal in this kind of gene therapy to erase ...
- Neuralink Cofounder Says New Company's Eye Implant Could Be "Ultimate" VR Techon January 3, 2023 at 1:42 pm
Science Corporeal After leaving Neuralink in 2021, Max Hodak is back with a brain-computer interface startup of his own — and he plans to create a next-generation prosthetic eye that could both cure ...
- The Cure is in our Genes- The future of gene therapyon January 2, 2023 at 8:14 pm
Gene therapy includes gene augmentation (restoring the functional protein) or gene editing (correcting the dysfunctional gene). In cell therapies, on the other hand, whole human cells or even ...
- Seattle man is first adult to get new gene therapy for visionon December 30, 2022 at 4:00 pm
The medication, called Luxturna, is injected in the eye and uses a harmless virus to deliver working versions of a gene to ... picked The Vision Center at CHLA, which offers the therapy to ...
- Blind Patients Hope Landmark Gene-Editing Experiment Will Restore Their Visionon December 26, 2022 at 9:00 pm
Kalberer and Knight are two of the first patients treated in a landmark study designed to try to restore vision to patients like ... light-sensing cells in the retina, devastating vision. A defect in ...
- New gene therapy to treat rare eye disease now available in Albertaon December 21, 2022 at 8:01 am
"The next generation of people with retinitis pigmentosa will have treatment when they're born, or early in their lives, so that their vision will be normal. They'll never have deterioration." The ...
- Gene Therapy Gel Offers New Hope Against Rare Blistering Diseaseon December 19, 2022 at 11:46 am
Gene Therapy Gel Offers New Hope Against Rare Blistering ... their bodies and can have eye inflammation that impairs their vision. Blisters and scarring also arise along the lining of the mouth ...
- Gene therapy gel offers new hope against rare blistering diseaseon December 15, 2022 at 10:53 am
An experimental gene therapy that's applied as a skin gel appears ... bodies and can have eye inflammation that impairs their vision. Blisters and scarring also arise along the lining of the ...
- Experimental gene therapy gel may help heal wounds from skin diseaseon December 15, 2022 at 8:13 am
RELATED Gene therapy may improve night vision of some with rare congenital blindness "We're helplessly watching blisters and wounds form, without any way to stop them," said Marinkovich ...
via Bing News